Blood Purification for the Treatment of Pathogen Associated Shock
Condition(s) studied
Investigational drug(s) / intervention(s)
Seraph-100 + State of the Art Care: Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) manufactured by ExThera Medical Corporation in Martinez, CA. The Seraph 100 filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin-coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins. The efficacy, safety, and risk-benefit data of the studies suggest that Seraph 100 is also safe and potentially beneficial by reducing the rate of thrombosis, without its use entailing a risk for patients. The achieved results from the above-mentioned testing and studies support the performance and safety of Seraph 100 consistent with the intended use. ExThera Medical concludes that the known and potential benefits of Seraph 100, when used to treat patients with pathogen associated shock, outweigh the known and potential risks when used according to the intended use.
State of the Art Care: "State of the Art care"is defined as the treatment algorithms outlined in the Surviving Sepsis Campaign for the treatment of septic shock, available at https://www.sccm.org/SurvivingSepsisCampaign/Home
Study summary
This study is a multi-center, randomized controlled feasibility trial to evaluate the initial safety and efficacy of a novel extracorporeal blood purification (EBP) therapy in critically ill patients with pathogen associated shock across 15 U.S. sites. Adults (18 years old and older) admitted to the ICU with all of the following:
• Pathogen associated shock defined as:
* The need for vasopressors to maintain mean arterial pressure (MAP) ≥ 65 mmHg despite adequate fluid resuscitation
* Presence of a pathogen detected in the bloodstream within 72 hours of screening using commercially available in-vitro diagnostic testing
Eligibility
Primary outcome measure(s)
- Efficacy - ICU-free days in the first 28 days — First 28 days
Alive and not in the ICU (for at least a fulle 24 hours) in the first 28 days from the time of randomization - Safety - Adverse Events — Discharge from hospital
SAEs and \>/= grade 3 AEs per CTCAE v5 evaluated from enrollment until the end of hospitalization
Trial sites (9)
| Facility | City | Region | Status |
|---|---|---|---|
| George Washington University | Washington D.C. | District of Columbia | |
| Southeast Georgia Health System, Inc. | Brunswick | Georgia | |
| University of Michigan | Ann Arbor | Michigan | |
| Mayo Clinic | Rochester | Minnesota | |
| Good Samaritan Hospital | Corvallis | Oregon | |
| Trinity Health Mid Atlantic-SMMC | Langhorne | Pennsylvania | |
| University of Texas Southwestern Medical Center | Dallas | Texas | |
| Methodist Hospital | San Antonio | Texas | |
| University of Texas Health Science Center at San Antonio (UT Health San Antonio) | San Antonio | Texas |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05011656 on ClinicalTrials.gov ↗ ← All trials in the USA